Active Needle is a medical device company that aims to prevent the problem of needle placement errors in ultrasound-guided needle interventional procedures. The technology allows for precision needle targeting.
days to go:
Expired
investment:
£147,514
Lighting Design, Luminaire Development and UK Manufacture. Our core products are street/ industrial lighting. LED lighting is the future and ALed's will continue to design and develop ground breaking products that challenge. Our design technology means we provide highly efficient lighting solutions that maintain a quality of light far longer than our competition. A £1.5 Billion spend on street lighting upgrades (UK) planned by 2020 provides the market for our continued growth.
days to go:
Expired
investment:
£393,256
Africa New Energies holds an oil exploration license in Namibia, where it has applied its unique surface exploration method to identify a gross unrisked prospective resource of 1.6 billion barrels of oil equivalent.
days to go:
Expired
investment:
Withheld
Antev Limited (Antev) is a clinical-stage biopharmaceutical firm which focuses on the evolution of a drug used for prostate cancer, Teverelix TFA. The company is working on growing its copyright protection and is currently developing phase IIb clinical plans for prostate cancer. Antev is a pre-revenue company that aims at increasing its shareholder value by progressing the development of teverelix TFA towards registration whose approval is anticipated from 2023 onwards. The proceeds will be used for production, IP development, working capital and to develop a phase IIb repeat dosing clinical trial in prostate cancer.
days to go:
Expired
investment:
Withheld
Aiming to prevent further deterioration and leakage of water and sewerage pipes, Aqualiner has developed their Melt in Place Pipe (MIPP). This patented technology consists of a sock insertion, which when heated, expands and melts onto the inner pipe and forms a solid glass-reinforced thermoplastic layer. This process can increase the longevity of existing pipes and is the only product of this type to be approved to be safe-for-use in drinking water pipes. The UK has more than 251,000 miles of water pipes, where almost 75,000 miles of pipes are classed as damaged.
Aqualiner firstly plans to sell the initial equipment in return for a small profit margin, but the materials and consumables used in the process will be sold to the licensed contractor directly as a second income stream. The third source of revenue is derived from fees charged to International territorial licensors for any Aqualiner sales.
The product has been developed with support from Anglian Water, Severn Trent Water and Yorkshire Water and is approved to be installed in US drinking water pipes.
days to go:
Expired
investment:
£642,471
Arcis Biotechnology provide nucleic acid sample preparation solutions. They have made the process of obtaining genetic material from biological samples less time consuming so it can be done in less than 3 minutes.
days to go:
Expired
investment:
£1,146,318
Belluscura aims at attending millions of people worldwide who are suffering from chronic lung diseases by providing them with the X-PLOR, portable, a lightweight, oxygen delivery device. It has developed it mainly to improve both the mobility and the life quality of the patients suffering from Chronic Obstructive Pulmonary Disease globally. It also has an exclusive license to a patented portable oxygen concentrator, the X-PLOR, that supplies 96% pure oxygen to patients 24/7. It's X-PLOR weights only 1.4kg and is 33% lighter, and provides 37% more oxygen per kg than its leading opponents. As smoke, pollution, and lives increase, the oxygen market will continue to grow from £1.1bn to £1.9bn by 2024. So, according to its market research, a 3% market share within 3 years could generate £46m in sales. With the funds raised, it is planning to extend its proprietary oxygen platform technology into other multi £bn markets such as wound care and sleep. Furthermore, it has filed patents on a next-generation portable artificial lung.
days to go:
Expired
investment:
£543,670
BiVictriX Therapeutics is a pharmaceutical company that are developing ADC's (Antibody Drug Conjugates) in the field of Oncology. They have invented a strategy that improves ADC selectivity towards cancer cells.
days to go:
Expired
investment:
£451,506
Carnot is developing hydrogen engines with key components manufactured from ceramics able to withstand fuel combustion temperatures, eliminating the need for cooling systems and doubling the efficiencies of modern engines. The company argues that modern engines waste on average one-third of fuel energy to cool systems that stop metallic components from melting. Carnot claims that its engines eliminate this waste doubling efficiency, halve fuel costs and CO2 and achieve net-zero operation by operating on biofuels and hydrogen benefiting the long haul transport, marine and primary off-grid power markets. Carnot has raised over £600,000 including a pre-seed round in 2020 for £357,000 at a pre-money valuation of £2 million, a £300,000 Innovate UK grant and another £300,000 Eureka Eurostar’s grant. Carnot has a 5-year, 3-phase exit strategy and will begin licensing its IP at the end of 2023 at which point it will begin generating revenue. It will eventually look for acquisition from one of its manufacturing partners in 2025 after demonstrating industry acceptance of its technology.
days to go:
Expired
investment:
£262,500
Cellmed is an immuno-oncology company that are developing treatments for ovarian cancer. Their lead product PROCURE a dendritic cell vaccine and they are now looking to expand the treatment to target solid tumors.
days to go:
Expired
investment:
£520,294
